Healthcare Global Enterprises Results: Latest Quarterly Results & Analysis

Healthcare Global Enterprises announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

• Revenue: Rs 4,946 million 12% YoY
• Adjusted EBITDA: Rs 941 million 21% YoY
• PAT: Rs 213 million  154% YoY

FY24 Financial Highlights:

• Revenue: Rs 19,121 million 13% YoY
• Adjusted EBITDA: Rs 3,374 million 11% YoY
• PAT: Rs 482 million 65% YoY

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “We experience a deep sense of fulfilment to report a consistent benchmark-beating performance across all fronts for the quarter and the fiscal year ending FY24. Year after year, HCG has achieved sustainable cancer care outcomes comparable to premier centers in the world, thanks to our unique value-based care model and focused factory approach providing patients with the right treatment at the right time, using best in class talent, knowledge, technology, and infrastructure.

Given the mounting incidence of cancer in recent years, India has prudently enhanced its cancer diagnosis and treatment processes in the guiding light of visionary crusaders like HCG. We prioritize a deep engagement in academics and research alongside an unflinching focus on patient outcomes. In the past year, we have made significant triumphs, including the successful completion if comprehensive genomic profiling for over 1,000 cancer patients, executing complex surgeries, and launching our all-in-one mobile application, among other feats.

Our extensive presence in 18 regions across nine states, with one-third of our centers located in tier-II and tier-III cities, underscores our sterling commitment of providing affordable and quality cancer care for every cancer patient across India. Our ability and agility to build heartfelt relationships with patients is built on a rock-solid foundation of compassion and trust, which truly sets us apart in this crucial sector. As we get ready to lock horns with new challenges and keep pace with the evolving paradigms of tomorrow, we earnestly resolve to make a bigger difference in the lives of patients, our most valued stakeholders.”

Raj Gore, CEO HealthCare Global Enterprises Ltd. added, “We are delighted to report that our revenues grew by 12% for Q4FY24 on YoY basis. Our Adjusted EBIDTA (excl. ESOP cost) for Q4FY24 stood at Rs 94 crore, a growth of 21% YoY, with margins standing at 19.0%, an increase of 140 bps compared to the same period last year.

Over the year, we have taken multiple steps to enhance our operations and improve our profitability. After consistently achieving organic growth for 3-4 years, we're now poised to expedite HCG's expansion through strategic acquisitions. In addition to our expansion efforts in Indore, we are committed to further strengthening our presence in Bangalore. We are currently in the process of establishing two hospitals with 125 beds in North Bangalore and White field area, slated to be operational within the next 12 to 15 months. These state-of-the-art facilities will enhance our capacity to cater to the growing cancer care needs of the region.

Alongside, to enhance the patient experience and streamline access to healthcare services, we have introduced the 'HCG CARE' smart app suite. This innovative platform provides patients with seamless access to their medical records and treatment information with just one click. The app would also help us consistently engage with patients post treatments, to continue monitor adherence to treatment and follow up to improve outcome. Already, the app has benefited over 56,000 outpatients, with active participation from 300 consulting doctors on the digital platform.

Our patient-centric vision continues to guide us in making a meaningful difference in the lives of those we serve by redefining healthcare through global innovation. We pledge to uphold our commitment to “Adding Life to Years” in the coming financial years as well.”

Result PDF

Healthcare Global Enterprises announced Q3FY24 & 9MFY24 results:

Financial Performance

• Revenue: Q3FY24 revenue reached Rs 4,699 million, marking an increase of 11% YoY. Over 9MFY24, the revenue climbed to Rs 14,175 million, reflecting a growth of 13% YoY.
• Adjusted EBITDA: The company reported an adjusted EBITDA of Rs 826 million for Q3FY24, achieving a 7% rise YoY. For 9MFY24, adjusted EBITDA was Rs 2,455 million, indicating an 8% YoY increase.
• Profit After Tax: The Profit After Tax (PAT) for Q3FY24 was Rs 57 million, a decrease of 24% YoY. While for 9MFY24, the PAT stood at Rs 269 million.

Revenue Breakup

• Mature Centers: Q3FY24 revenue from mature centers was 790 million.
• Emerging Centers: Revenue from emerging centers in Q3FY24 reached 1,015 million.

EBITDA Breakup - Mature vs Emerging Centers

• Mature Centers: Demonstrated a YoY growth of 19.3%, with an increased revenue of Rs 3,323 million in Q3FY24 compared to Rs 3,065 million in Q3FY23.
• Emerging Centers: Shown a YoY growth of 65.7%, with a revenue hike from Rs 122 million in Q3FY23 to Rs 126 million in Q3FY24.

Operational KPIs (Oncology)

• OPD Footfall: Q3FY24 experienced 110,000 footfalls, as compared to 91,000 in Q3FY23.
• Chemo Sessions Administered: The company administered 36,000 chemo sessions in Q3FY24 whereas it was 34,000 in Q3FY23.
• LINAC Capacity Utilizations: Utilization increased to 61% in Q3FY24 from 60% in Q3FY23.
• In-Patient Bed Occupancy: Saw a slight decrease to 52% in Q3FY24 from 57% in the previous year.

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, “India is at the cusp of significant demographic change leading to a doubling of population aged over 60 years by 2050. Cancer incidence is expected to increase by 77% during this period. HCG, with its network of 22 Cancer Centers and expansion plans is poised to play a dominant role in serving the diagnostic and treatment needs of the forecasted demand.

HCG's performance for the quarter serves as evidence of its progress in advancing towards focused cancer care, where research and collaboration are the key drivers for improving patient outcomes. By leveraging these unique value propositions, we are able to provide targeted treatments such as adaptive radiotherapy and immunotherapy to our patients. Moreover, our integration of technology into patient care processes, including computational work and Al platforms, allows us to continuously be on the leading edge of the change, creating a differential in the way cancer has evolved.

At HCG, we have always embraced technology and innovation to be at the forefront of advancement in cancer care. We have consistently adopted cutting-edge solutions to ensure that we provide the highest quality healthcare to our patients. Our ability to deeply connect with patients is built on a foundation of compassion and trust that is unmatched, which is what truly sets HCG apart from others in our field. We remain committed to continue making a meaningful difference in the lives of those we serve in making Cancer a chronic disease."

Result PDF

Healthcare Global Enterprises announced Q1FY24 results:

• Revenue of Rs 4,607 million in Q1FY24, up 13% YoY.
• EBITDA of Rs 764 million in Q1FY24, up 5% YoY.
• Profit After Tax of Rs 110 million in Q1FY24, up 17% YoY.
• Overall ARPOB stood at Rs 39,686 vs. Rs 38,286 in Q1FY23.
• Overall AOR stood at 66.9% vs. 61.0% in Q1FY23, a rise of 590 bps.

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, “HCG’s oncology network, through its presence and depth, uniquely positions the company to address the growing cancer burden in India holistically, while delivering quality cancer care and outcomes.

HCG's role today goes beyond mere service provision, extending into pioneering research and academia. We consistently encourage our medical professionals to delve into research, clinical trials, and active participation in global medical conferences and academic pursuits. We are currently working on the low dose immunotherapy & also collaborating with various MNC’s for developing technologies and AI based framework for treatments.

HCG strives to be the trusted healthcare partner for every individual battling cancer. We are honored to have earned the trust of our patients and the communities we serve and remain committed to upholding that trust every day."

Result PDF

Healthcare Global Enterprises announced Q3FY23 results:

• Q3FY23 & 9MFY23:
  • Revenue Rs 4,247 million is up by 19% for Q3FY23 YoY.
  • Adjusted EBITDA  Rs 812 million is up by 28% for Q3FY23 YoY.
  • Profit after Tax Rs 75 million turns positive for Q3FY23 YoY.
  • Revenue Rs 12,527 million is up by 21% for 9MFY23 YoY.
  • Adjusted EBITDA Rs 2,378 million is up by 35% for 9MFY23 YoY.
  • Profit after Tax Rs 209 million turns positive for 9MFY23 YoY.

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, of HealthCare Global Enterprises Ltd. said, “At HCG, we strive to provide the best-in-class treatments for our patients across the value chain. We have been focusing on consistently upgrading our skill set with deep domain knowledge, upgradation of technology & urge to treat cancer for the best possible outcomes for every single patient under the HCG horizon.

Technology and innovation play a pivotal role in enhancing healthcare systems, increasing access to healthcare services, and reducing the costs of therapies and consultations. It is the intelligent deployment of technology that serves the larger cause of healthcare. At HCG, patient care is approached holistically based on risk and severity of disease - from pre-admission to post-discharge – and is aimed at enhancing outcomes, lowering costs, and bettering resource management. Whether Linac technology, Teleradiology, Bioinformatics, Genomics, Robotic surgery, Digital pathology, or Adaptive AI, HCG's technology adoption is unflinchingly focused on patient outcomes.

Our focus has been on Oncology in conjunction with local partners, has helped us built a strong legacy as a World-class Oncology Treatment Center &Institution across India.”

Mr. Raj Gore, CEO of HealthCare Global Enterprises Ltd. added, “I am extremely happy to share that we have once again outgrown the industry growth, and our revenues for Q3FY23 grew by 19% on a YoY basis to Rs 4,247 million. With accelerated awareness in the society for Cancer care &diagnosis and HCG, being a trusted brand in the medical fraternity for Cancercare, we expect the revenue growth to improve and margins to enhance due to operating leverage play. 

We have seen growth in our volumes & patient count across modalities and with increased awareness, investments in digital technology, marketing initiatives & positive outcomes, we are optimistic of sustaining the growth momentum.

At HCG, we believe in patient-centric care, focusing on accessible oncological services, advanced treatments, and high-quality care & outcomes. Over the years we have emerged as a responsible brand earning the trust of thousands of patients and the admiration of the community which has led us to be the leader in most of the markets, we are present in. Going forward, we continue to invest in HCG brand and penetrate deeper into the markets of our core geography and attain leadership position in newer territories through superior treatment & outcomes.”

Result PDF

Healthcare Global Enterprises announced Q2FY23 results:

• Q2FY23:
  • Revenue is Rs 4,200 million; up 19% YoY for Q2FY23 
  • Adjusted EBITDA is Rs 810 million; up 28% YoY for Q2FY23 
  • PAT is Rs 74 million; turns positive for Q2FY23 YoY
• H1FY23
  • Revenue Rs 8,281 million; up 23% YoY for H1FY23 
  • Adjusted EBITDA is Rs 1,566 million, up 40% YoY for H1FY23 
  • PAT is Rs 134 million; turns positive for H1FY23 YoY

BS Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd, said, "HCG chain of dedicated cancer centres is consistently moving up the value chain of high-quality clinical care powered by high-end technology. Our Bangalore COE, which is one of India’s largest dedicated cancer care hospitals has recently launched India’s first Varian Ethos™ therapy, an Artificial Intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. It uses augmented intelligence, a convergence of people and artificial intelligence (AI) working together for better outcomes & higher success rates while maintaining the quality of life. This game-changing radiation therapy personalizes cancer care using adaptive intelligence based on the patient’s anatomy and the position of the tumour at the time of treatment.

At HCG, we are equally focused and engaged in academics and research, we are very proud to announce that we have over 170 fellowship programs and different DNB programs in oncology, not only in Bangalore, but also in Tier 2, and Tier 3 cities. In research, for October, we have had nine new publications, and a significant number of them have been podium presentations, till date we have published more than 750 research papers.

Our focus has been on Oncology in conjunction with local partners, which has helped us build a strong legacy as a World-class Oncology Treatment Center & Institution across India."

Raj Gore, CEO HealthCare Global Enterprises Ltd, added, "We are happy to report another strong financial performance for the quarter that ended September 2022. Our consolidated revenue for Q2FY23 stood at Rs 4,200 mn, a growth of 19% on a YoY basis. Our focused efforts on cost rationalization coupled with strong revenue growth have resulted in a marginal expansion of 230 bps, leading to an adjusted EBITDA margin of 18.9% in H1FY23. Adjusted EBIDTA for H1FY23 stood at Rs 1,566 mn as compared to Rs 1,121 mn in H1FY22, a growth of 40% on YoY basis. As a result of consistent revenue growth & margin expansions, our reported PAT (excl. Exceptional items) has increased to Rs 74 Mn for Q2FY23 as compared to Rs 8.3 Mn in Q2FY22.

While our mature centres continue to show higher than the market growth rate, the growth strategies implemented for the emerging centres have started showing promising results. Jaipur centre has more than doubled its revenue whereas Kolkata and Mumbai have grown by 40% & 30% respectively on a Y-o-Y basis in the current quarter

Our differentiated and specialised cancer care along with strong brand positioning have enabled us to attain leadership position in 13 out of 18 locations where we are present. Going forward, we will continue to invest in HCG brand to make it the preferred choice for cancer patients across India. We are optimistic of improving our market share & strengthening our leadership position."

Result PDF

Healthcare Global Enterprises announced Q1FY23 Result :

• Overall ARPOB stood at Rs. 38,454 vs. Rs. 36,316 in Q1 FY22, a growth of 5.9%
• Overall AOR stood at 64.6% vs. 57.8% in Q1 FY22, a rise of 680 basis points
• EXISTING CENTERS:
  • ARPOB stood at Rs. 40,606 vs. Rs. 35,979 in Q1 FY22, a growth of 12.9%
  • AOR stood at 64.0% vs. 59.4% in Q1 FY22, a rise of 460 basis points
  • RoCE stood at 19.0% vs. 15.4% in FY22, a rise of 360 basis points
• NEW CENTERS:
  • ARPOB stood at Rs. 32,968 vs. Rs. 32,295 in Q1 FY22, a growth of 2.1%
  • AOR stood at 66.1% vs. 53.5% in Q1 FY22, a rise of 1,260 basis points
  • RoCE stood at -4.6% vs. -8.3% in FY22

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, HCG is a leading Oncology care provider, which is patient centric, technology-oriented and outcome based. Our focus has been on Oncology in conjunction with local partners in some areas, which has built a strong legacy as a World-class Oncology Institution and a go-to brand for oncological treatment & services across India. Our focus on strong clinical talent, good infrastructure, technology, and timely upgradation of the same has enhanced or ability to deliver exceptional clinical outcomes equal to or better than global standards. And in the very near future, we are putting together the data on Head & Neck and Breast Cancer on these outcomes. HCG today is not only a service provider but has taken a lead role in Research and Academics. Recently, we have acquired Next Generation Sequencer and in the process of acquiring circulating tumour cells (CTC platform). These additions are already enhancing our capabilities in precision diagnosis leading to early detection of recurrent tumours and genomic guided therapy. We have a separate tumour board for this with relevant expertise. In addition, we have introduced Enterprise RIS PACS, in collaboration with Siemens for the first time in the country for AI based precision imaging which will enhance our research capabilities. Further, HCG is introducing first of its kind in the country, AI enabled Adoptive Radiotherapy in our Centre of Excellence which will provide precision radiation oncology.

Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd. added, We are happy to report robust growth for quarter ended June 2022. Our consolidated revenues for Q1FY23 grew by 26% on YoY basis and we have reported PBT of Rs. 10 crs for Q1FY23 as compared to loss of Rs. 9 crs in Q1FY22. We are also happy to report that we have been able to successfully accelerate the financial performance for HCG over the last 8 quarters. Our revenues have increased by ~1.7x since Q2FY21 on a quarterly run rate basis. Correspondingly our EBIDTA in absolute terms have grown by 2.4x times over the last eight quarters and have been able to achieve consecutive PBT positive quarter. We have been working on multiple fronts to take HCG to greater heights by constantly improving holistic value that we offer to our patients and thus create value for the business in a sustainable manner. Four key areas of our strategic roadmap that we are currently working on are: 1) Digital transformation, 2) Cost optimization and efficiency enhancement, 3) Growth of Medical Value Travel, 4) Inorganic acquisitions. We are confident of maintaining our growth momentum going forward.

Result PDF

Healthcare Global Enterprises announced Q4FY22 results:

• Q4FY22:
  • Consolidated Income from Operations (“Revenue”) was Rs 3,646 Mn as compared to Rs 2,981 million in the corresponding quarter of the previous year, reflecting a YoY growth of 22.3%
  • Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was Rs 661 million, as compared to Rs 438 million in the corresponding quarter of the previous year, a growth of 51.2% YoY
  • Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was Rs 631 million, as compared to Rs 394 million in the corresponding quarter of the previous year, a growth of 60.4% YoY
  • Operating EBITDA for Existing centers was Rs 610 million, a growth of 38.6% YoY, reflecting an Operating EBITDA margin of 22.0%
  • Operating EBITDA from New centers was Rs 21 million, as compared to loss of Rs (46) million in the corresponding quarter of the previous year
  • Proforma PAT was Rs 67 Mn, as compared to a loss of Rs (155) million in the corresponding quarter of last year, after adjusting below and tax implications there of;
    • Onetime project fee of Q4’22 Rs 25 million
    • ESOP Scheme expense of Q4’22 Rs 19 million
• FY22:
  • Consolidated Income from Operations (“Revenue”) was Rs 13,978 million as compared to Rs 10,134 million in the previous year, reflecting a YoY growth of 37.9%
  • Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”), was Rs 2,380 million, as compared to Rs 1,266 million in the corresponding quarter of the previous year, a growth of 88.0% YoY
  • Operating EBITDA for Existing centers was Rs 2,308 million, reflecting an Operating EBITDA margin of 21.5%
  • Operating EBITDA from New centers was Rs 72 million, as compared to loss of Rs (157) million in the previous year
  • Proforma PAT was Rs (13) Mn, as compared to a loss of Rs (980) million in the previous year, after adjusting below and tax implications there of;
    • Impairment of NCR project Rs 472 million
    • Exceptional gain of Rs (1419) million arising out of Strand and Suchirayu acquisition
    • Onetime project fee of FY’22 Rs 45 million
    • ESOP Scheme expense of FY’22 Rs 55 million
    • DTA recognized on tax expense through the year, on account of discontinuation of Kochi project, Rs (25) million

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “HCG has carved a niche as the cancer care destination of choice across all key areas of clinical, research, and academic excellence. Our phenomenal growth over the years bears testimony to the fact that cancer can be considered just like any other chronic disease, however curable. This year, we have added over 40 oncologists to our growing team which takes our doctor’s strength to over 450 which is the largest in the country in Oncology. We continue to employ the latest and most advanced techniques of cancer diagnosis and treatment enabling us to serve a greater number of patients with an objective of quality outcome. In a landmark development, we introduced Microsoft HoloLens, the next-gen holographic headset, heralding a new era of virtual reality at our enterprise. Through a pioneering industry initiative, we have brought healthcare training and medical education to the Metaverse by publishing 200 hours of virtual reality content across multiple subspecialties.

Patients are our most important stakeholders. To serve them more effectively, we have invested in a robust digital platform employing cutting-edge technologies for end-to-end patient engagement. The crux of our high quality of care across the length and breadth of the country is to ensure the right treatment, the very first time.

Going forward, we believe our robust cancer care ecosystem will continue to deliver impressive returns. Cancer therapies are undergoing a defining change every 75 days. Thanks to our enhancement of knowledge and innovations, we are able to relentlessly manage the cancer care in a progressive way. Backed by our research labs and the clinical trials, we are uniquely positioned to enhance our diagnostic capabilities and offerings, as also redefine precision medicine with end-to-end expertise spanning bioinformatics, genomics and research. This will enable us to deliver tangible patient outcomes with greater precision over the long term.

Academics and Research go hand in hand with patient care and our capabilities in this regard makes us the benchmark in cancer care treatment. We are happy to share that our Centre of Excellence in Bangalore has been ranked #1 in the country.”

Result PDF

Healthcare Facilities Healthcare Global Enterprises declares Q3FY22 result:

• Q3’22 Revenue grew by 30.7% YoY
  • HCG centers grew by 30.8 %
  • Milann centers grew by 28.5 %
  • Revenue from Vaccination is 43Mn, was 250 Mn in Q2’22
  • International business yet to return to its BAU level
• Q3’22 Operating EBITDA
  • Existing centers : INR 566 Mn (20.6% margin vs 18.2% margin in Q3-FY21)
  • New centers : INR 52 Mn (vs. loss of INR (21) Mn in Q3-FY21)
  • Contribution from Vaccination is 12Mn, was 58.3 Mn in
• Q2’22 Q3’22 Proforma PAT : INR 12 Mn is after adjusting below and tax implications there of;
  • Impairment of NCR Project INR 472 Mn
  • Exceptional gain of INR 19 Mn arising out of Suchirayu acquisition
  • One time project fee of Q3’22 INR 20 Mn
• YTD-FY22 Revenue grew by 44.4 % YoY
  • HCG centers: 44.0 %
  • Milann centers: 53.1 %
• YTD-FY22 Operating EBITDA
  • Existing centers : INR 1,698 Mn (21.3% margin vs 17.6% margin in YTD-FY21)
  • New centers : INR 51 Mn (vs. loss of INR (111) Mn in YTDFY21)
• YTD’22 Proforma PAT: INR -80 Mn is after adjusting below and tax implications there of;
  • Impairment of NCR Project INR 472 Mn
  • Exceptional gain of INR 1419 Mn arising out of Strand and Suchirayu acquisition
  • Onetime project fee of Q3’22 INR 20 Mn

Result PDF

Highlights:

• Consolidated Income from Operations (“Revenue”) was INR 3,520 mn as compared to INR 2,479 mn in the corresponding quarter of the previous year, reflecting a YoY growth of 42.0% 
• Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was INR 650 mn, as compared to INR 340 mn in the corresponding quarter of the previous year, a growth of 91.1% year-on-year and 19.0% quarter-on-quarter 
• Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was INR 617 mn, as compared to INR 300 mn in the corresponding quarter of the previous year, a growth of 105.7% year-on-year and 20.5% quarter-on-quarter 
• Operating EBITDA for Existing centers was INR 598 mn, a growth of 81.7% year-on-year and 12.4% quarter-on-quarter, reflecting an Operating EBITDA margin of 21.9% 
• Operating EBITDA from New centers was INR 19 mn, as compared to loss of INR 29 mn in the corresponding quarter of the previous year and loss of INR 19 mn in the previous quarter 
• Consolidated Profit after Taxes and Minority Interest (“PAT”) was a profit of INR 1,031 mn, as compared to loss of INR 223 mn in the corresponding quarter of the previous year

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “At HCG, we believe in patient centric care and focus on accessible oncological services, advanced treatments and high-quality care and outcomes. Over the years, we have emerged as a responsible brand, earning the trust of thousands of patients and admiration of the community. Our focus on advanced technology, our ability to deliver exceptional clinical outcomes and a team of dedicated specialists equip us with capabilities to further the oncology care continuum while emerging as a pioneer and leader in oncology.

The Company has turned in industry-leading revenue growth this quarter, which is also backed by improving profitability, especially among the new centres that have not yet reached the mature stage of operations. The growth opportunities ahead of us in the domestic business is quite strong and we are also seeing a turnaround in the number of international patients visiting our centres with the easing of travel restrictions. Milaan, our fertility center has also performed very well with a growth of 57% on the back of a new leadership team under Shailesh Guntu aided by our focus on digital outreach which is delivering us the desired results.

Overall, HCG under the dynamic leadership of Raj Gore, our CEO, is positioned very uniquely with a strong pipeline as well as a de-levered balance sheet to deliver superior growth and profitability but with a clear focus on tangible outcomes for all our stakeholders, most important of which are our patients for whom positive outcomes from the disease is the best return.” 

Result PDF